April 1, 2014

Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.

October 17, 2013

Prasco Labs will distribute an authorized generic for reducing serum phosphate in patients with end-stage renal disease under a contract with Shire, Prasco said Thursday.

May 1, 2013

Prasco Labs has signed a deal with WellSpring Pharmaceutical Corp. to market an authorized generic version of a drug for a rare tumor disorder.

January 7, 2013

Drug maker Prasco Labs has launched an authorized generic version of a drug used to treat heavy menstrual bleeding, the company said.

August 20, 2012

Prasco Labs is distributing an authorized generic version of a respiratory drug under an agreement with the branded drug's manufacturer.

April 11, 2012

Prasco Labs will market an authorized generic version of a drug used to treat diarrhea caused by a bacterial infection, the company said Wednesday.

April 10, 2012

Prasco Labs has launched an authorized generic version of a blood-pressure drug made by Shionogi, the company said.

January 12, 2012

Prasco Labs will act as the distributor for an authorized generic version of a Shire anticonvulsant drug, the company said Thursday.

December 6, 2011

Generic drug maker Prasco Labs has named Christopher Arington its vice chairman and CEO.

October 20, 2011

Prasco Labs will make authorized generic versions of two psychiatric drugs made by Eli Lilly under a partnership between the two companies announced Thursday.

October 18, 2011

Prasco Labs announced it will serve as the exclusive U.S. distributor and pharmaceutical services provider for a line of branded prescription drugs.

July 25, 2011

Prasco Labs has contracted to sell an authorized generic version of a painkiller made by Shionogi, Prasco said Monday.

February 22, 2011

Prasco Labs will distribute an authorized generic version of an ulcerative colitis treatment made by Shire in the event that any other company steps forward to file an abbreviated new drug application for the drug.